A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects

Abraham Nudelman; Irit Gil-Ad; Nava Shpaisman; Igor Terasenko; Hanna Ron; Kinneret Savitsky; Yona Geffen; Abraham Weizman; Ada Rephaeli

doi:10.1021/jm7012453

A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects

Abraham Nudelman^*, Irit Gil-Ad, Nava Shpaisman, Igor Terasenko, Hanna Ron, Kinneret Savitsky, Yona Geffen, Abraham Weizman, Ada Rephaeli

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

Original language	English
Pages (from-to)	2858-2862
Number of pages	5
Journal	Journal of Medicinal Chemistry
Volume	51
Issue number	9
DOIs	https://doi.org/10.1021/jm7012453
State	Published - 8 May 2008
Externally published	Yes

Access to Document

10.1021/jm7012453

Cite this

@article{55c3f917183c4533a9858409b0e65d2d,

title = "A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects",

abstract = "The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.",

author = "Abraham Nudelman and Irit Gil-Ad and Nava Shpaisman and Igor Terasenko and Hanna Ron and Kinneret Savitsky and Yona Geffen and Abraham Weizman and Ada Rephaeli",

year = "2008",

month = may,

day = "8",

doi = "10.1021/jm7012453",

language = "אנגלית",

volume = "51",

pages = "2858--2862",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects

AU - Nudelman, Abraham

AU - Gil-Ad, Irit

AU - Shpaisman, Nava

AU - Terasenko, Igor

AU - Ron, Hanna

AU - Savitsky, Kinneret

AU - Geffen, Yona

AU - Weizman, Abraham

AU - Rephaeli, Ada

PY - 2008/5/8

Y1 - 2008/5/8

N2 - The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

AB - The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

UR - http://www.scopus.com/inward/record.url?scp=42949169475&partnerID=8YFLogxK

U2 - 10.1021/jm7012453

DO - 10.1021/jm7012453

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 18363346

AN - SCOPUS:42949169475

SN - 0022-2623

VL - 51

SP - 2858

EP - 2862

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 9

ER -

A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects

Abstract

Access to Document

Other files and links

Fingerprint

Cite this